Skip to content
Perfectlifebeauty Perfectlifebeauty

Female beauty is the most precious.

  • Home
  • Female beauty
  • Personality
  • Maquillage
  • Cosmetics
  • Aesthetic medicine
  • Fashion
Perfectlifebeauty
Perfectlifebeauty

Female beauty is the most precious.

2386 views, 11/09/202211/09/2022

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following fourth quarter investor conferences.

Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Thursday, November 17, 2022, at the Westin NY Grand Central Hotel

Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

Panel Presentation – Diagnostics Tool Time: Novel Tests in Specialized Markets on Thursday, December 8, 2022, at 10:00 a.m. EST at the Fontainebleau Miami Beach Hotel

About Exagen Inc.

Exagen (Nasdaq: XGN) is a leading provider of autoimmune diagnostic, prognostic, and monitoring testing solutions. Exagen is a patient focused, discovery driven organization built on the success of AVISE testing and is investing in its product pipeline to support patients throughout their autoimmune diagnosis and treatment journeys. The goal at Exagen is to assist patients, physicians, and payors by enabling precision medicine. Exagen is located in San Diego County with clinical and research and development laboratories in Vista, CA.

For more information, please visit Exagen.com and follow @ExagenInc on Twitter.

Forward Looking Statements

Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: the COVID-19 pandemic may continue to adversely affect its business, financial condition and results of operations, including as a result of slowdown in its operations as well as those of its suppliers and courier services, impeding patient movement and interruptions to healthcare services causing a decrease in test volumes, disruptions to the supply chain of material needed for its tests causing an increase in cost per test, its sales and commercialization activities and its ability to receive specimens and perform or deliver the results from its tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; third party payors not providing coverage and adequate reimbursement for Exagen’s testing products or promoted therapeutics, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2021 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor RelationsExagen Inc. Ryan [email protected] 760.560.1525

CompanyExagen Inc.Kamal Adawi, Chief Financial [email protected]  760.477.5514

Aesthetic medicine

Post navigation

Previous post
Next post

Comments (2)

  1. Raul O'Reilly says:
    11/09/2022 at 2:12 am

    Hello! How do you feel about young composers?

    Reply
  2. Meda Hoeger says:
    11/09/2022 at 11:52 am

    Wow 🤪🤪

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • Aesthetic medicine (32)
  • Cosmetics (26)
  • Fashion (35)
  • Female beauty (30)
  • Financial tips (1)
  • Maquillage (32)
  • Personality (27)

Advertisement

  • ‘I thought my boyfriend of 10 years was going to propose – then he told me he was trans’10/08/2022
    I consider myself an LGBTQ+ ally. But I wasn’t prepared for the shock and confusion I’d feel when the person I thought I’d spend my life with told me their secretIt was 3am and I’d had a lot to drink; two reasons why I was pressing my boyfriend of 10 years on…
  • In the frame: a close look at the world of spectacles10/09/2022
    A new exhibition focuses on sight – from myopic 13th-century monks to the fabulous frames of Iris Apfel and Jarvis CockerThe world is getting softer around the edges. It’s blurry and confusing – are you squinting at the screen or are your arms getting too sho…
  • Why middle child syndrome is a myth, according to new research10/10/2022
    Research found that siblings have a small impact on personality when it comes to development and adulthood
  • Cantu Beauty’s Global Vice President Talks About The Power Of Reaching Within10/11/2022
    Dametria Kinsley, Global Vice President at Cantu Beauty, shares more on her journey in the beauty industry, hopes for the future of Diversity, Equity, and Inclusion, and tips for the next generation of leaders in the realm.
  • Dr. Eliza Parker Joins MedSpa Partners10/11/2022
    MedSpa Partners Inc. ("MSP") is proud to welcome Dr. Eliza Parker and her team at Cadella Aesthetics to its top-tier North American medical aesthetics...

Advertisement

  1. Meda Hoeger on Exagen Inc. to Participate in Fourth Quarter Investor Conferences11/09/2022

    Wow 🤪🤪

  2. Reid Wilkinson on By bucking norms, Ashley McBryde became one of country’s most respected, and unlikeliest, stars11/09/2022

    Very cool photo 🌈☀️

  3. Godfrey Rowe on By bucking norms, Ashley McBryde became one of country’s most respected, and unlikeliest, stars11/09/2022

    At the proper level 🥰

  4. Loy Little on By bucking norms, Ashley McBryde became one of country’s most respected, and unlikeliest, stars11/09/2022

    Yes, that's what you need🎉

December 2022
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
« Nov    

If you subscribe, we'll send you goodies straight to your inbox.

Thank You For Subscribing

Advertisement

  • About
  • Contact us
  • Privacy Policy

Copyright © 2022 All Right Reserved By PERFECTLIFEBEAUTY.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok